Emerging molecular-targeted therapies—the challenging case of endometrial cancer
Abstract
Keywords
Full Text:
PDFReferences
National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2012 [document on the Internet]. Bethesda:NIH; 2015 [cited date]. Available from: http://seer.cancer.gov/csr/1975_2012/.
Growdon WB, Roussel BN, Scialabba VL, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol 2011; 121(1):212-217. doi: 10.1016/j.ygyno.2010.11.039.
Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011; 8(5):261-271. doi: 10.1038/nrclinonc.2010.216.
Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497(7447):67-73. doi: 10.1038/nature12113.
Peiro G, Peiro FM, Ortiz-Martinez F, et al. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment. Hum Pathol 2013; 44(2):218-225. doi: 10.1016/j.humpath.2012.05.008.
Bradford LS, Rauh-Hain A, Clark RM, et al. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecol Oncol 2014; 133(2):346-352. doi: 10.1016/j.ygyno.2014.02.022.
Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol 2015; 136(2):246-253. doi: 10.1016/j.ygyno.2014.12.019.
Coleman RL, Sill MW, Thaker PH, et al. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015; 138(1):30-35. doi: 10.1016/j.ygyno.2015.04.005.
English DP, Bellone S, Cocco E, et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol 2013; 209(5):465.e1-465.e9. doi: 10.1016/j.ajog.2013.07.020.
Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015; 33(8):930-936. doi: 10.1200/JCO.2014.58.3401.
Meyer LA, Slomovitz BM, Djordjevic B, et al. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer 2014; 24(4):713-717. doi: 10.1097/IGC.0000000000000118.
Kwok B , Rawson R , Alsabeh R et al. Lung adenocarcinoma with contiguous in-situ follicular lymphoma involving <5% of the total lymphoid cells (Abstract LW38.1). Paper presented at the XVth meeting of the European Association for Haematopathology; Uppsala, Sweden; 2010 Sep 25–30.
Owens SR, Hartman DJ. In situ Follicular lymphoma (Abstract LW25). Paper presented at the XVth meeting of the European Association for Haematopathology; Uppsala, Sweden; 2010 Sep 25–30.
Alsabeh R, Abdelhalim F, Kwok B, et al. In-situ follicular lymphoma involving about 2% of the total lymphoid cells (Abstract LW103). Paper presented at the XVth meeting of the European Association for Haematopathology; Uppsala, Sweden; 2010 Sep 25–30.
Vlahovic G, Meadows KL, Uronis HE, et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol 2012; 70(1):95-102. doi: 10.1007/s00280-012-1889-8.
Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2014;132(3):585-592. doi: 10.1016/j.ygyno.2014.01.015.
Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129(1):22-27. doi: 10.1016/j.ygyno.2012.12.022.
Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29(24):3278-3285. doi: 10.1200/JCO.2010.34.1578.
Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010;117(3):473-476. doi: 10.1016/j.ygyno.2010.02.022.
Kollmannsberger C, Hirte H, Siu LL, et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol 2012;23(1):238-244. doi: 10.1093/annonc/mdr063.
Oza AM, Pignata S, Poveda A, et al. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. J Clin Oncol 2015; published online on June 15. doi: 10.1200/JCO.2014.58.8871.
Tsoref D, Welch S, Lau S, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 2014;135(2):184-189. doi: 10.1016/j.ygyno.2014.06.033.
Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 2013;108(5):1021-1026. doi: 10.1038/bjc.2013.59.
Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129(3):486-494. doi: 10.1016/j.ygyno.2013.02.019.
Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007;109(7):1323-1330. doi: 10.1002/cncr.22545.
Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26(26):4319-4325. doi: 10.1200/JCO.2007.15.8808.
Leslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127(2):345-350. doi: 10.1016/j.ygyno.2012.07.127.
Zhang X, Kyo S, Nakamura M, et al. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells. Cancer Lett 2014;345(1):106-114. doi: 10.1016/j.canlet.2013.11.020.
Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116(1):15-20. doi: 10.1016/j.ygyno.2009.09.025.
Konecny GE, Finkler N, Garcia AA, et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 2015;16(6):686-694. doi: 10.1016/S1470-2045(15)70159-2.
Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2012;127(3):538-543. doi: 10.1016/j.ygyno.2012.08.020.
Mackay HJ, Buckanovich RJ, Hirte H, et al. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol 2012;125(1):136-140. doi: 10.1016/j.ygyno.2011.11.042.
Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;29(16):2259-2265. doi: 10.1200/JCO.2010.32.6397.
McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 2007;105(2):508-516. doi: 10.1016/j.ygyno.2007.01.019.
Dizon DS, Sill MW, Schilder JM, et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135(3):441-445. doi: 10.1016/j.ygyno.2014.10.001.
Castonguay V, Lheureux S, Welch S, et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014;134(2):274-280. doi: 10.1016/j.ygyno.2014.05.016.
DOI: http://dx.doi.org/10.30564/amor.v1i1.4
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Ines Vasconcelos

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.